# A Relative Measurement of Oxidative Stress in NAFLD Through Cyclic Voltammetry Method for Clinical Translation

**Authors:** Dixa Sharma, Bhalendu S. Vaishnav, Nupur Pandya, Pratik Pataniya, C. K. Sumesh, Palash Mandal

PMC · DOI: 10.1155/grp/9948444 · 2025-04-16

## TL;DR

This study uses a new electrochemical method to measure oxidative stress in nonalcoholic fatty liver disease patients, showing potential for clinical use.

## Contribution

A novel cyclic voltammetry method is introduced to measure oxidative stress in NAFLD with high accuracy and potential for clinical translation.

## Key findings

- The study found significant changes in anodic current in steatohepatitis patients compared to healthy individuals.
- The electroanalytical method achieved less than 1.3% error in measuring oxidative stress in human plasma.
- The method could detect disease status and monitor treatment response in NAFLD patients.

## Abstract

A potential contributing factor in the development of various metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) could be oxidative stress and the production of reactive oxygen radicals. A high level of lipid peroxidation, including oxidative stress, can cause irreversible effects. We investigated the consequences of NAFLD on the reducing power of the liver in patients through plasma antioxidant capacity using screen-printed electrodes (SPEs). The study includes a total of 67 patient's population with steatosis (n = 29) and steatohepatitis (n = 38). Anodic current intensity (la), anodic wave area (S), and the biological sample oxidation potentials can be determined via cyclic voltammetry (CV) analysis. The enzyme glutathione peroxidase (GPx) and products of oxidative damage such as malondialdehyde (MDA), advanced glycation-end product (AGE), total status of oxidants (TOS), nitric oxide (NO), and cytokines analysis (qRT-PCR) of key mediators such as PNPLA3 in lipid metabolism, TIMP1 in fibrosis, and proinflammatory cytokines like NF-κB, TNF-α, and IL-6, which are crucial for understanding NAFLD progression were recorded to further validate the CV obtained results along with and morphological changes through scanning electron microscope (SEM). The developed method measured oxidative stress with an error of less than 1.3% in human plasma samples, wherein the steatohepatitis caused a spike modification in the anodic current AC520 and AC972 (p < 0.01) compared to healthy humans. The presented electroanalytical methodology could be widely used for easy and rapid subjects' disease status detection. In addition to monitoring the response of subjects to treatment and providing nutritional supplements, these results may also be used for screening specific populations.

## Linked entities

- **Genes:** PNPLA3 (patatin like domain 3, 1-acylglycerol-3-phosphate O-acyltransferase) [NCBI Gene 80339], TIMP1 (TIMP metallopeptidase inhibitor 1) [NCBI Gene 7076], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790], TNF (tumor necrosis factor) [NCBI Gene 7124], IL6 (interleukin 6) [NCBI Gene 3569]
- **Proteins:** GPX2 (glutathione peroxidase 2)
- **Diseases:** nonalcoholic fatty liver disease (MONDO:0013209)

## Full-text entities

- **Genes:** PNPLA3 (patatin like domain 3, 1-acylglycerol-3-phosphate O-acyltransferase) [NCBI Gene 80339] {aka ADPN, C22orf20, iPLA(2)epsilon}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, TIMP1 (TIMP metallopeptidase inhibitor 1) [NCBI Gene 7076] {aka CLGI, EPA, EPO, HCI, TIMP, TIMP-1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}
- **Diseases:** metabolic diseases (MESH:D008659), fibrosis (MESH:D005355), NAFLD (MESH:D065626), steatohepatitis (MESH:D005234)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12017943/full.md

---
Source: https://tomesphere.com/paper/PMC12017943